Dr. Behnam Ahmadian Baghbaderani, global head of process development for cell and gene technologies, Lonza, introduces best practices required to de-risk the commercial manufacturing of cell and gene therapies. Learn the principles of commercialization readiness and how to address logical steps in process development.
After entering Phase 3, cell and gene therapies experience nearly five times more discontinuations or significant delays due to CMC issues than monoclonal antibodies. Two members of Lonza’s operational excellence team share the secrets behind recent successes in commercializing and producing commercial cell and gene therapies.
In this webinar, explore strategies to meet the quality and regulatory requirements of cell and gene therapies, and discover more about Lonza's New Product Introduction (NPI) process for CGT manufacturing, including how to identify issues early on, reduce quality and compliance risks, and avoid delays and rework.
This website uses cookies to ensure you get the best experience on our website. Learn more
